Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UK (The EMPA-KIDNEY Collaborative Group The Lancet Digital Health 2024)
🤔 EMPA KIDNEY analysis by CKD diagnosis
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)
🤔 EMPA Kidney sub-group analysis by DM and ACR status
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)
Here We KDIGO Again: Lupus Nephritis 2024
New KDIGO guidelines since 2021, Lupus Nephritis is seeing lots of new therapeutics in the pipeline.
🤔 Albuminuria reduction drives Finerenone's kidney benefit
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes (Agarwal et al, Annals IM 2023)
🤔 Cuff size and BP: the Cuff (SZ) trial
Effects of Cuff Size on the Accuracy of Blood Pressure Readings. The Cuff(SZ) Randomized Crossover Trial (Ishigami et al JAMA IM 2023)
🤔 Does intensive BP Lowering worsen orthostatic hypotension?
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease. An Individual Participant Meta-Analysis (Juraschek, JAMA 2023)
🤔 Risk of AIN with PPI/ICI overstated
Proton pump inhibitors and the risk of acute kidney injury in cancer patients receiving immune checkpoint inhibitors: A Danish population-based cohort study (Munch, International Journal of Cancer 2023)
🤔 E-alerts in AKI, the ELAIA-2 trial
A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes (Wilson, Nature Communications 2023)
🤔 RCT comparing Cefepime with Pip/Taz and AKI
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial (Quian, JAMA 2023)
🤔 Glucose absorption drives cystogenesis in PKD
Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease (Li, Nature Communications 2023)
🤔 Ketogenic diets in ADPKD
Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial (Cukoski, Cell Reports Medicine 2023)
🤔 GWAS in IgA Nephropathy
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy (Kiryluk, Nature Genetics 2023)
🤔 Sibeprenlimab in IgA Nephropathy
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (Mathur, NEJM 2024)
🤔 Sparsentan in IgA Nephropathy
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Rovin, Lancet 2023)
🤔 Severe hypocalcemia with Denosumab in Dialysis
Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients (JAMA 2024)
🤔 Cystatin C better predicts outcomes in Sweden
Association of Low Glomerular Filtration Rate With Adverse Outcomes at Older Age in a Large Population With Routinely Measured Cystatin C (Annals IM 2024)
🤔 Flozination reduces kidney stones
Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes (JAMA 2024)
🤔 Maternal kidney mass associates with gestational and fetal outcomes
Any reduction in maternal kidney mass makes a difference during pregnancy in gestational and fetal outcome. (Kidney International 2024)
🤔 Adjusting Tolvaptan based on Urine osmolality in ADPKD
Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD (KI Reports Jan 2024)